



CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

To the Board of Directors of **SHILPA MEDICARE LIMITED**.

1. We have reviewed the accompanying statement of unaudited standalone financial results of SHILPA MEDICARE LIMITED ("the Company") for the quarter ended 30th June, 2022 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **BRAHMAYYA & CO.**
Chartered Accountants
Firm's Regn No. 0005135



K. Shrawan.
(K.SHRAVAN)

Partner

Membership No. 215798

Place : Hyderabad

Date : 11.08.2022

UDIN: 22215798 AOVNH84472

Shilpa Medicare Limited

Registered office: # 12-6-214/A-1, Hyderabad Road, Raichur- 584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com, Telephone -+91-8532-238494

CIN No. - L85110KA1987PLC008739

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. In Lakhs, except per equity share data)

Sl. No.	Particulars	Quarter ended			Previous year ended
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Continuing Operations:				
1	Income				
	Revenue from operations	6,083.42	7,287.29	10,526.07	35,695.18
	a) Net Sales/income from operations	4,369.61	5,221.82	10,382.77	32,609.03
	b) Service Income and License fees	1,713.82	2,065.47	143.31	3,086.15
	Other Income	1,262.82	1,033.56	963.77	4,086.20
	Total Income	7,346.24	8,320.85	11,489.84	39,781.38
2	Expenses				
	a) Cost of material consumed	1,546.69	1,845.78	2,629.05	7,518.73
	b) Purchase of stock-in-trade	94.20	-	414.85	677.73
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(689.15)	(788.92)	184.83	(317.86)
	d) Employee benefits expense	2,794.44	3,005.43	2,429.20	11,056.99
	e) Finance cost	265.87	173.15	248.99	905.37
	f) Depreciation and amortisation expenses	1,042.06	1,029.18	710.96	3,481.77
	g) Other expenses	1,887.13	3,379.55	3,609.10	14,590.97
	Total Expenses	6,941.23	8,644.17	10,226.98	37,913.70
3	Profit before tax and exceptional items (1-2)	405.01	(323.32)	1,262.86	1,867.68
4	Exceptional items- (Income)/Expenses (Pl refer note no: 03)	-	10.00	-	(880.90)
5	Profit Before Tax from continuing operations (3+4)	405.01	(333.32)	1,262.86	2,748.58
6	Tax Expense of continuing operations	19.57	(38.86)	377.83	732.75
	-Current tax	70.92	(58.24)	329.00	480.23
	-Deferred tax (Net of MAT credit)	(51.35)	19.38	48.83	252.52
7	Profit for the Period/year from continuing operations (5-6)	385.44	(294.46)	885.03	2,015.83
	Discontinued Operations:				
8	Profit/(loss) before tax for the period/year from discontinued operations (refer note no: 05)	8,148.77	5,544.58	1,883.03	16,540.71
9	Tax (expense)/credit of discontinued operations	(2273.73)	1,704.66	253.39	4,457.74
10	Profit for the period/year from discontinued operations (8-9)	10,422.50	3,839.92	1,629.64	12,082.97
11	Net profit for the period/year (7+10)	10,807.94	3,545.46	2,514.66	14,098.80
12	Other comprehensive income (OCI) from continuing operation				
	A. Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the defined benefit (liability)/asset	-	(122.95)	141.30	18.36
	B. Items that will be reclassified subsequently to profit or loss				
	Gain / (Loss) on derivative instrument (net)	-	-	16.81	22.73
	Total other comprehensive income (net of tax)(A+B)	-	(122.95)	158.11	41.09
13	Other comprehensive income (OCI) from discontinuing operations				
	A. Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the defined benefit (liability)/asset	(144.96)	159.61	0.00	159.61
14	Total other comprehensive income/(expenses)for the period/year from continued operations	385.44	(417.41)	1,043.14	2,056.92
15	Total other comprehensive income/(expenses)for the period/year from discontinued operations	10,567.46	3,680.31	1,629.64	11,923.36
16	Total comprehensive income for the period / year (14+15)	10,952.90	3,262.90	2,672.77	13,980.28
17	Paid up equity share capital (par Value Rs.1/- each, fully paid)	868.02	868.02	815.27	868.02
18	Reserves i.e Other equity				205,698.77
19	Earnings per equity share (par value Rs.1/- each):	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Continuing Operations:				
	Basic (Rs.)	0.44	(0.34)	1.09	2.41
	Diluted (Rs.)	0.44	(0.34)	1.09	2.41
	Discontinued Operations:				
	Basic (Rs.)	12.01	4.42	2.00	14.46
	Diluted (Rs.)	12.01	4.42	2.00	14.46
	Total Operations:				
	Basic (Rs.)	12.45	4.08	3.08	16.87
	Diluted (Rs.)	12.45	4.08	3.08	16.87

Date: 11 August 2022
Place: Raichur



Omprakash Inani
Chairman
DIN 0130385



CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of **SHILPA MEDICARE LIMITED**.

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SHILPA MEDICARE LIMITED (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and its share of the net loss after tax and total comprehensive loss of its associates and joint Ventures for the quarter ended 30th June, 2022 (the "Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the result of the following Subsidiaries/ Associates/Joint Ventures:
 - a. Koanaa Healthcare Limited, UK (Wholly owned subsidiary Company)
 - b. Koanaa Healthcare Limited, Austria (Wholly owned subsidiary Company)
 - c. Zatortia Holdings Limited (Wholly Owned Subsidiary Company)
 - d. Shilpa Therapeutics Private Limited (Wholly Owned Subsidiary Company)
 - e. INM Technologies Private Limited (Wholly Owned Subsidiary Company)
 - f. INM Nuvent Paints Private Limited (Step down Subsidiary Company)
 - g. Makindus, Inc (Subsidiary Company)
 - h. MAIA Pharmaceuticals, Inc (Associate Company)
 - i. Reva Medicare Private Limited (Joint Venture Company)
 - j. Reva Pharmachem Private Limited (Associate Company)
 - k. Shilpa Pharma Inc (Wholly owned subsidiary Company)





CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

- l. Sravathi Advance Process Technologies Private Limited (Joint Venture Company)
 - m. Shilpa Biologicals Private Limited (Wholly Owned Subsidiary Company)
 - n. Shilpa Biocare Private Limited (Formerly known as "Shilpa Albumin Private Limited" - Wholly Owned Subsidiary Company)
 - o. Koanna Healthcare Canada Inc (Wholly owned subsidiary Company)
 - p. Shilpa Pharma Lifescience Limited (Formerly Known as Shilpa Corporate Holding Private Limited - Wholly owned subsidiary Company)
 - q. FTF Pharma Private Limited (Wholly owned subsidiary Company)
 - r. Auxilla Pharmaceuticals and Research LLP (Joint Venture)
 - s. Sravathi AI Technologies Private Limited (Joint Venture Company)
 - t. Indo Biotech SDN.BHD, Malaysia (Wholly Owned Subsidiary Company)
 - u. Koanna International FZ-LLC, Dubai (Wholly Owned Subsidiary Company)
 - v. Koanna Healthcare, Spain S.L (Wholly Owned Subsidiary Company)
 - w. Vegil Labs Private Limited (Wholly Owned Subsidiary Company)
 - x. Shilpa Lifesciences Private Ltd (Step down Subsidiary Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements of eight subsidiaries included in the consolidated unaudited financial results, whose interim financial statements reflects total revenue of Rs. 1364.97 lakhs, total net loss after tax of Rs (3768.56) lakhs and total comprehensive loss of Rs. (3767.48) lakhs for the quarter ended 30th June 2022, as considered in the consolidated unaudited financial results. The statement also includes the Group's share of net loss after tax of Rs. (73.30) lakhs and total comprehensive loss of Rs. (73.30) lakhs for the quarter ended 30th June 2022 as considered in the consolidated unaudited financial results, in respect of four joint ventures and one associate, whose interim financial statements have not been reviewed by us. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associate and Joint ventures is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.
7. The Statement includes the interim financial statements of nine subsidiaries which have not been reviewed, whose interim financial statements reflect total revenue of Rs. 838.20 lakhs, total net loss after tax of Rs. (296.16) lakhs and total comprehensive loss of Rs. (296.16) lakhs for the quarter ended 30th June 2022, as considered in the consolidated unaudited financial results. These interim financial statements have been approved and furnished to us by the Management and our conclusion on the statement, in so far as it relates to the affairs of these subsidiaries, is





CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

based solely on such interim financial statements. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

8. In case of one foreign associate interim financial statements for the quarter ended 30th June, 2022 are not concluded and have not been furnished to us by the Management, and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts included in respect of this associate is based solely on the information available for the period ended 31st December, 2022. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion on the statement is not modified in respect of the above matter.

for **BRAHMAYYA & CO.**
Chartered Accountants
Firm's Regn No. 000513S



K. Shravan
(K.SHRAVAN)

Partner

Membership No. 215798

UDIN: 22215798AOVNNI5072

Place : Hyderabad
Date : 11.08.2022



Accounting for
all stakeholders

Shilpa Medicare Limited

Registered office : # 12-6-214/A-1, Hyderabad Road, Raichur -584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com., Telephone --+91-8532-238494

CIN No. - L85110KA1987PLC008739

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. In Lakhs, except per equity share data)

Sl No.	Particulars	Quarter ended			Previous year ended
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	Revenue from operations	26,115.66	34,059.50	23,735.67	114,552.27
	a) Net Sales/income from operations	23,491.94	31,221.18	22,714.79	108,837.93
	b) Service Income and License fees	2,623.72	2,838.32	1,020.88	5,714.34
	Other Income	810.16	549.17	198.96	1,424.54
	Total Income	26,925.83	34,608.67	23,934.63	115,976.82
2	Expenses				
	a) Cost of material consumed	8,754.63	9,438.26	7,331.77	38,174.89
	b) Purchase of stock-in-trade	1,974.51	(78.72)	718.80	849.07
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(333.51)	1,996.64	(454.42)	(702.15)
	d) Employee benefits expense	7,285.79	7,342.62	5,785.46	26,448.65
	e) Finance cost	958.64	934.58	1,031.65	4,116.52
	f) Depreciation and amortisation expenses	2,241.98	2,234.28	1,763.32	7,980.19
	g) Other expenses	6,377.32	7,987.88	7,165.87	29,396.25
	Total Expenses	27,259.35	29,855.55	23,342.45	106,263.42
3	Profit before share of profit of joint venture and associates, exceptional items and tax (1)- (2)	(333.52)	4,753.13	592.18	9,713.40
4	Share of Profit / (loss) of Joint venture and associates, net of tax	(73.30)	(100.85)	(74.98)	(366.03)
5	Profit before tax and exceptional items (3-4)	(406.82)	4,652.28	517.20	9,347.36
6	Exceptional items- (Income)/Expenses(pl refer note no: 04)	-	11.80	-	(879.11)
7	Profit Before Tax (5+6)	(406.82)	4,640.48	517.20	10,226.47
8	Tax Expense	(641.12)	1,685.94	355.78	4,168.27
	-Current tax	1,494.43	944.60	557.13	3,404.31
	-Deferred tax (Net of MAT credit)	(2,135.55)	741.34	(201.35)	763.96
9	Profit for the Period / year before non-controlling interest (7)-(8)	234.30	2,954.54	161.42	6,058.20
10	Share of (loss)/profit attributable to non-controlling interest	(149.44)	(0.36)	(2.61)	(8.02)
11	Profit after taxes attributable to owners of the Parent Company for the period / year (9-10)	84.85	2,954.90	158.81	6,066.23
12	Other comprehensive income (OCI)				
	A. Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the defined benefit liability/asset Gain/(Loss) (net of tax)	146.04	(294.25)	139.26	(159.06)
	B. Items that will be reclassified subsequently to profit or loss				
	Gain / (Loss) on derivative instrument (net of tax)	-	-	16.81	22.73
	Total other comprehensive income(net of tax)(A+B)	146.04	(294.25)	156.07	(136.33)
13	Total comprehensive income for the period / year (11)+(12)	230.90	2,660.65	314.88	5,929.90
14	Paid up equity share capital (par Value Rs.1/- each, fully paid)	868.02	868.02	815.27	868.02
15	Reserves i.e other equity				181,351.46
16	Earnings per equity share (par value Rs.1/- each)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Basic (Rs.)	0.10	3.40	0.19	7.26
	Diluted (Rs.)	0.10	3.40	0.19	7.26



Notes:

- 1 The above unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2022 in respect of Shilpa Medicare Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on Aug 11, 2022. The above results have been subject to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- 2 These financial results have been prepared in accordance with Indian Accounting Standards('Ind-AS') notified under section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 During the year ended March 31, 2022, the Company has recognised an exceptional income of Rs.890.90 Lakhs, realised on account of reduction of investment in one foreign subsidiary
- 4 During the year ended March 31, 2022, Seven investors infused Rs.29,751.00 Lakhs against preferential issue of equity shares of the Company which represents 6.08% shareholding of the Company. The consideration was received and equity shares were allotted on November 12, 2021. Calculation of EPS for the year ended March 31, 2022 is based on weighted average equity.
- 5 On 30 June, 2022, The Company has completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company for a consideration of Rs. 48,630.00 lakhs .

Gain on disposal of assets/ liabilities amounting to Rs. 6,292.51 lakhs which is exceptional in nature has been disclosed under the discontinued operations.

Accordingly, results of API business for the quarter ended June 30, 2022 and comparatives for previous reporting periods has been disclosed as discontinued operations in the standalone results.

Particulars	INR in lakhs			
	Quarter ended			Year ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Amount	Amount	Amount	Amount
Total income from third parties	18,545.27	23,188.06	13,521.96	75,203.92
Inter company sales to units in continuing operations	1,221.47	2,611.76	1,578.60	7,724.56
Total income	19,766.74	25,799.82	15,100.56	82,928.48
Total expenses	17,910.49	20,255.24	13,217.53	66,387.78
Profit before tax and exception gain from discontinued operation	1,856.26	5,544.58	1,883.03	16,540.71
Exceptional Gain on Disposal of API Business.	6,292.51	-	-	-
Profit before tax from Discontinued Operations for the period	8,148.77	5,544.58	1,883.03	16,540.71
Tax Expense/ (Credit) of discontinued operations	{2,273.74}	1,704.66	253.39	4,457.74
Profit for the period from discontinued operations	10,422.51	3,839.92	1,629.64	12,082.97

There is Nil tax impact on the Exceptional Gain made from slump sale of one of its Business undertakings to its 100% wholly owned subsidiary U/S 47(iv) of the Income Tax Act, 1961

- 6 The Operating segment of the Company is " Pharmaceuticals", as the Chief Operating Decision Maker reviews business performance at an overall Company level as one segment . Therefore, segment reporting as per Ind-AS 108 is not applicable to the Company.
- 7 Prior period/year figures have been reclassified wherever required to conform to the classification of the current period/year. Also refer note 05 above.

Date: 11 August 2022

Place: Raichur



Omprakash Inani
Chairman
DIN 0130385